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Chronic calcium pyrophosphate crystal arthritis is a
clinical consequence of the formation and deposition
of these crystals in joints and can result in persistent
arthritis. Curative treatment would require the removal
of crystals from joints and tissues, but to date all
agents tested have proven ineffective. Management
of the inflammatory manifestations of chronic calcium
pyrophosphate disease includes glucocorticoids,
non-steroidal anti-inflammatory drugs, or colchicine,
and responses are usually satisfactory. However, in
some patients, the response to these agents is poor
or they are contraindicated. Methotrexate had been
reported as a promising option in small case series;
however, in a recent issue of Arthritis Research & Therapy,
a clinical trial failed to confirm the anticipated
benefits. Here, we discuss some issues that might
have influenced the results of the study, before deciding
to abandon methotrexate as a therapeutic option for
patients with chronic calcium pyrophosphate arthritis.with recurrent (more than three in a 6-month period)Editorial
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forming a prospective controlled study of methotrexate
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consequence of the formation and deposition of these
crystals in joints and can result in persistent arthritis usu-
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unless otherwise stated.ineffective [2]. Therefore, the management of CPPD relies
on the control of the inflammatory manifestations, a
scenario in which glucocorticoids, non-steroidal anti-
inflammatory drugs, and colchicine can work well [3].
However, in some patients, the response to these agents
is poor or contraindications for employing them arise,
especially as CPPD occurs most often in older patients.
Those with persistent disease despite traditional therapy
constitute a troublesome subgroup of patients.
MTX seemed a promising option for these patients, as
reported in small case series by Chollet-Janin and col-
leagues [4] and our group [5]. Conversely, other series
from France noted no effects [6]. To clarify the effect-
iveness and safety of MTX, Finckh and colleagues [1]
performed this clinical trial, which has failed to confirm
the anticipated benefits. Before MTX is abandoned as a
therapeutic option for patients with CPPD, it merits
analyzing whether any methodological issue might have
influenced the results of the trial.
In the study by Finckh and colleagues, they appear to
have enrolled two quite different forms of CPPD: some
episodes of acute arthritis (likely separated by asymp-
tomatic intercritical periods) and others with persistent,
polyarthritis-like inflammatory disease. As the authors
commented, the size of the study sample is lower than
intended, as only 26 pairs were recruited (from the 28-pair
calculated sample size) and only seven completed the
study, performing an intention-to-treat analysis. Also, the
authors selected DAS44 (44-joint disease activity score) as
the main evaluation technique, and the sample size was
also calculated on the basis of results of previous trials in
rheumatoid arthritis (RA). However, around 25% of en-
rolled patients had recurrent CPP arthritis, and evalua-
tions at the start of the study or both at the start and the
end may have occurred during an intercritical asymp-
tomatic period, hence the low DAS44 results and the
lack of change. Only 12 patients showed a polyarticular
presentation, the only group where these estimations. This is an Open Access article distributed under the terms of the Creative
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ness of the evaluation technique in a group and the low
statistical power of the whole study must be taken into
account when considering the results of the study.
The diagnosis of CPPD is performed on the basis of
consistent clinical features and the identification of the
crystals in synovial fluid (SF). In the case of episodes of
acute arthritis, the relationship of the crystals with the
joint inflammation appears clear, provided that no alter-
native diagnosis, such as an infection occurring at a joint
containing CPP crystals, is reasonable. However, for poly-
articular inflammatory disease, the relationship is less
clear-cut. Chondrocalcinosis is a common finding in older
age groups (approximately 18% in patients between 75
and 79 years old) [7], and the presence of crystals in SF of
previously inflamed joints is constant [8]. In the absence
of a negative association between CPP crystals and other
diseases, we would expect that one in five patients who
initiate a polyarthritis at this age would show chondrocal-
cinosis on X-rays and likely CPP crystals in their SF.
Therefore, the presence of chondrocalcinosis or of a num-
ber of CPP crystals in SF in an older patient with persist-
ent polyarthritis and features consistent with those of
another disease—such as a seronegative RA (not a rare
condition [9])—might imply the coexistence of the two
disorders, RA being the main driver of inflammation; this
could explain the possible response to MTX.
The study by Finckh and colleagues also outlines the
difficulties of producing evidence in the treatment of less
common diseases, especially when there are no eco-
nomic interests in supporting the research. It also shows
the difficulties posed when the clinical presentations are
diverse and the reasons for considering them together
or apart are not solidly grounded, thus hampering the
interpretation of the results. Cross-over designs such as
in this trial may facilitate valid conclusions in these
circumstances.
We consider that this study should not be taken as
definitive, and for those older patients with a seronega-
tive symmetrical polyarthritis showing chondrocalcino-
sis or CPP crystals (or both) in their SF, MTX still
merits a trial.
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